Yazılar

Neuralink Expands Human Trials, 12 People Now Using Brain Implants

Elon Musk’s Neuralink announced Tuesday that 12 people worldwide have received its brain implants, marking steady progress in its clinical rollout.

Key Details

  • Patient Numbers: Up from 7 in June, when partner Barrow Neurological Institute confirmed its involvement.

  • Usage Stats: Collectively, patients have logged 2,000 days of implant use and over 15,000 hours of activity, using the device to control both digital and physical tools through thought.

  • Trials Abroad: A new clinical study will launch in the UK, partnering with University College London Hospitals and Newcastle Hospitals.

  • Funding: Neuralink raised $650 million in June to support expansion.

Background

  • Neuralink began human trials in 2024 after overcoming U.S. FDA safety objections that initially blocked approval in 2022.

  • The company’s implants are aimed at restoring movement and communication for people with severe paralysis, representing a major step in brain-computer interface (BCI) technology.

Outlook

  • The trials will help Neuralink test long-term safety, reliability, and potential new medical applications.

  • If successful, the technology could pave the way for broader use cases — from medical rehabilitation to advanced human-computer interaction.

Eli Lilly Unveils AI-Powered TuneLab to Speed Drug Discovery

Eli Lilly (LLY.N) announced on Tuesday the launch of TuneLab, an artificial intelligence and machine learning platform designed to give biotech companies access to advanced drug discovery models trained on decades of Lilly’s research data.

The platform represents more than $1 billion in proprietary data investments and aims to level the playing field by letting smaller biotech firms access the same AI-driven tools Lilly scientists use internally.

Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists,” said Daniel Skovronsky, Lilly’s chief scientific officer.

Two biotech firms — Circle Pharma and insitro — are already early partners. Circle will apply TuneLab’s tools to cancer drug development, while insitro will contribute new AI models for small molecule discovery, enhancing TuneLab’s capabilities.

The move reflects a broader industry shift toward AI in research and development. Analysts at Jefferies forecast that AI-related R&D spend could reach $30–40 billion by 2040, as drugmakers adopt AI for discovery, testing, and reducing reliance on animal studies, in line with FDA goals.

TuneLab operates on datasets covering hundreds of thousands of unique molecules. In exchange for access, biotech partners provide their own training data, further strengthening the platform’s predictive power and long-term value.

Trump-Musk Rift Raises Regulatory Risks for Elon Musk’s Business Empire

Elon Musk’s deteriorating political relationship with former President Donald Trump may expose his vast business empire to heightened regulatory scrutiny across multiple U.S. agencies. As political tensions escalate, the risk that regulators may more aggressively oversee Musk’s various companies has become a growing concern. Below is an overview of the key U.S. regulators with authority over Musk’s enterprises, and the potential challenges ahead:

Federal Communications Commission (FCC)
The FCC oversees the allocation of spectrum critical to SpaceX’s Starlink satellite internet service. In April, the FCC launched a review of its longstanding spectrum sharing rules, potentially affecting SpaceX’s access to expanded frequencies necessary to enhance its coverage. While the review aims to modernize spectrum usage, it may also result in stricter rules or delays for SpaceX, depending on the political climate and regulatory stance.

Food and Drug Administration (FDA)
The FDA regulates clinical trials for Neuralink, Musk’s brain implant company. While Neuralink has secured FDA approval for initial human trials, earlier safety concerns cited by the agency in 2023 remain relevant as trials progress. Any missteps or adverse events in ongoing studies could prompt the FDA to halt or delay the company’s development timeline.

Environmental Protection Agency (EPA)
SpaceX’s Starbase launch facility in Texas falls under the EPA’s jurisdiction for environmental compliance, particularly regarding wastewater discharge and environmental impact assessments under the National Environmental Policy Act. Rocket launches and tests, which have included multiple explosions, may invite further scrutiny, particularly if environmental groups or political adversaries exert pressure on federal agencies.

National Highway Traffic Safety Administration (NHTSA)
Tesla’s Full Self-Driving (FSD) technology remains under active investigation by NHTSA, especially regarding its performance under poor visibility conditions. The agency recently requested detailed information on Tesla’s robotaxi service set to launch in Austin, Texas, this month. Any regulatory findings could impact Tesla’s ability to scale its self-driving services.

Federal Aviation Administration (FAA)
The FAA proposed a $633,000 fine against SpaceX last year for license violations during launches. With ongoing investigations and the potential for future launch failures, the FAA holds significant leverage over SpaceX’s launch schedule and licensing requirements.

Securities and Exchange Commission (SEC)
Musk continues to face legal battles with the SEC, including litigation related to his 2022 acquisition of Twitter (now X). The regulator is also reportedly investigating Neuralink, raising additional legal exposure. Any adverse findings could impact Musk personally as well as his companies’ access to capital markets.

Federal Trade Commission (FTC)
The FTC oversees data privacy and antitrust compliance for social media platforms, including X. The agency is currently investigating whether certain media watchdog groups coordinated advertiser boycotts of X, a situation Musk claims is anti-competitive. The FTC’s broader mandate to protect consumer privacy could result in further investigations, particularly regarding data protection for minors.

Political Climate Raises Stakes
While these agencies have long held authority over Musk’s operations, his prior friendly ties to Trump may have provided a degree of political insulation. The recent breakdown in their relationship removes that buffer, potentially leaving Musk more exposed to adversarial regulatory action depending on future election outcomes and shifting political alliances.

With businesses spanning electric vehicles, space exploration, telecommunications, brain-computer interfaces, and social media, Musk’s cross-sector reach makes him uniquely vulnerable to regulatory actions from multiple federal agencies simultaneously.